3,279 reports of this reaction
1.4% of all TERIPARATIDE reports
#19 most reported adverse reaction
DRUG DOSE OMISSION is the #19 most commonly reported adverse reaction for TERIPARATIDE, manufactured by Eli Lilly and Company. There are 3,279 FDA adverse event reports linking TERIPARATIDE to DRUG DOSE OMISSION. This represents approximately 1.4% of all 227,333 adverse event reports for this drug.
TERIPARATIDE has an overall safety score of 78 out of 100. Patients taking TERIPARATIDE who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is a less commonly reported adverse event for TERIPARATIDE, but still significant enough to appear in the safety profile.
In addition to drug dose omission, the following adverse reactions have been reported for TERIPARATIDE:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 3,279 FDA reports for TERIPARATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 1.4% of all adverse event reports for TERIPARATIDE, making it a notable side effect.
If you experience drug dose omission while taking TERIPARATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.